Diagnostic Approach for Secondary Skin Involvement of Lymphoma

Tissue Diagnosis Requirements

The American Society of Clinical Oncology recommends obtaining excisional biopsy whenever possible, rather than punch biopsy, and using at least 4mm diameter to ensure adequate tissue architecture 1, 2, 3
Multiple biopsies from different sites may be required if initial sampling is non-diagnostic, as stated by the British Association of Dermatologists 4, 5
The essential immunohistochemical panel for B-cell lineage confirmation and characterization includes CD20 and/or CD79a, surface and cytoplasmic immunoglobulins, Bcl-2, Bcl-6, and CD10, according to the American Society of Hematology 1, 2, 3
For T-cell lineage, CD3 is used for T-cell confirmation, and CD4 and CD8 for subset identification, as recommended by the British Association of Dermatologists 4, 5
Additional markers such as Ki-67 proliferative index and CD21 or CD35 are also used to distinguish neoplastic from reactive follicles, as stated by the American Society of Hematology 1, 2, 3

The European Society for Medical Oncology recommends complete physical examination documenting all sites of lymphadenopathy and organomegaly, as well as assessment for B symptoms, for systemic staging evaluation 6, 7
Excisional biopsy of any bulky palpable peripheral lymph nodes is preferred over core or fine needle biopsy, according to the British Association of Dermatologists 4, 5
Mandatory blood work includes complete blood count with differential, comprehensive metabolic panel, lactate dehydrogenase, and flow cytometry of peripheral blood, as recommended by the American Society of Clinical Oncology 4, 6, 7, 5
Imaging studies such as CT scans of chest, abdomen, and pelvis are mandatory for all patients with secondary skin involvement, according to the European Society for Medical Oncology 4, 6, 7, 5
Consider PET/CT for more accurate staging, particularly in aggressive lymphoma subtypes, as recommended by the European Society for Medical Oncology 6, 7

The immunophenotype pattern is decisive in distinguishing primary vs. secondary cutaneous lymphoma, with strong Bcl-2, Bcl-6, and CD10 expression in follicular structures indicating systemic follicular lymphoma, according to the American Society of Hematology 1, 2, 3
CD5+ cyclin D1+ indicates mantle cell lymphoma, and CD5+ CD23+ with dim CD20 indicates chronic lymphocytic leukemia/small lymphocytic lymphoma, as stated by the American Society of Hematology 1, 2, 3
Do not rely on morphology alone, and immunohistochemistry is mandatory to distinguish reactive from neoplastic processes, according to the American Society of Hematology 1, 2, 3

CD20 is the most sensitive marker for mature B‑cell lymphomas in routine practice and is expressed in the vast majority of B‑cell neoplasms. 8
CD79a provides the highest specificity alongside CD20; using both together yields optimal sensitivity and specificity for mature lymphoid neoplasms. 8, 9, 10, 11
PAX5 serves as a reliable backup marker when CD20 and CD79a are negative or equivocal, remaining positive in nearly all B‑cell neoplasms. 8, 9, 10, 11

Surface and cytoplasmic immunoglobulins (sIg/cIg) confirm B‑cell lineage and reveal monotypic expression on frozen (sIg) and paraffin (cIg) sections. 8, 9, 10, 11

CD3 should be included simultaneously to quantify admixed reactive T‑cells. 8, 9, 10, 11
Strong co‑expression of Bcl‑2, Bcl‑6, and CD10 in follicular structures indicates systemic follicular lymphoma with skin involvement rather than a primary cutaneous process. 8, 9, 10
CD5 and cyclin D1 are both negative in primary cutaneous marginal zone lymphoma; both are positive in mantle‑cell lymphoma, while CD5‑positive/cyclin D1‑negative pattern suggests chronic lymphocytic leukemia. 8, 9, 10

Ki‑67 assesses proliferative fraction and helps distinguish neoplastic from reactive follicles. 8, 9, 10, 11
CD21 or CD35 visualize follicular dendritic cell networks and residual reactive follicle architecture. 8, 9, 10, 11
MUM‑1 and FOXP1 assist in differentiating cutaneous B‑cell lymphoma subtypes and identifying secondary systemic involvement. 8, 9, 10, 11

Biopsy size: Punch biopsies should be at least 4 mm in diameter to preserve tissue architecture for reliable immunophenotyping. 8, 9, 10, 11
Recommended initial panel: Perform CD20 + CD79a + CD3 staining to establish B‑cell lineage and exclude T‑cell neoplasms. 8
If CD20/CD79a are negative or equivocal, add PAX5 immediately to rescue lineage identification.
If CD20, CD79a, and PAX5 are all negative, incorporate Oct2 and Bob1 before concluding a non‑B‑cell process.
After confirming B‑cell lineage, apply subtyping markers (CD5, CD10, Bcl‑2, Bcl‑6, cyclin D1) guided by morphology and clinical context. 8